Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2021-02-05
2021-02-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Role Of Empiric Dilation In Patients With Dysphagia With Normal Endoscopy
NCT01444066
Esophageal Atresia: a Natural Experiment of the Effects of Oral Inoculation on the Gut Microbiome
NCT04901546
The Use of Domperidone for Gastroparesis
NCT01378884
Mucosal Impedance and Eosinophilic Esophagitis
NCT01953575
Intestinal Permeability and Gastroparesis
NCT04894656
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental Thickener
Powder thickener
Experimental Thickener
Use to thicken liquids
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Experimental Thickener
Use to thicken liquids
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject is diagnosed with dysphagia.
* Subject is under the care of a Speech and Language Therapist and is currently using a thickener.
* Subject currently has normal GI function.
* Subject is interested in participating in the study, willing to comply with the study protocol and product.
* Subject who is able to consent and is able to evaluate the product.
Exclusion Criteria
* Subject at high risk of aspiration with oral fluids requiring nil by mouth and enteral tube feeding.
* Subject has impaired renal function.
* Subject has liver failure, decompensated chronic liver disease, active hepatitis B or C receiving treatment, or hepatic encephalopathy.
* Subject has severe dementia or unable to communicate or consent or delirium, eating disorder, history of significant neurological or psychiatric disorder affecting abilities to answer questions, alcoholism, substance abuse or other conditions that may interfere with study product consumption or compliance with study protocol procedures.
* Participant is known to be allergic or intolerant to any ingredient found in the study product.
* Participation in another study that has not been approved as a concomitant study.
* Subject has a clinical condition that is contraindicated with this product such as hepatic and renal disease.
* Subject has a clinical condition which may interfere with gastrointestinal tolerance.
* Subject is pregnant.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Abbott Nutrition
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rebecca Stevenson
Role: STUDY_CHAIR
Abbott Nutrition
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DA26
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.